Sorintellis

Sorintellis is a Montreal-based life sciences technology company transforming clinical drug development through artificial intelligence. We are on a mission to D.O.P.E. the Pharma Pipeline—Design, Optimize, Prioritize, and Execute—by transforming clinical trials with AI. Our AI-powered decision-support platform enables pharmaceutical companies, CROs, biotechnology firms, and life sciences investors to design optimized trials, operate with greater efficiency, predict risk and probability of success, and evaluate portfolios with confidence across the clinical development lifecycle. At the core of Sorintellis is TrialsBank, a proprietary, large-scale, multimodal clinical-trial database built, curated, and validated over several years by pharmaceutical and clinical-development experts. TrialsBank integrates hundreds of thousands of longitudinal Phase trials enriched with scientific, clinical, operational, regulatory, commercial, and financial features. Powered by this foundation, Sorintellis’ AI models assess the probability of success of drug development programs across multiple dimensions—scientific, operational, phase-transition, regulatory, and commercial—enabling smarter trial design, improved execution, pipeline prioritization, dynamic portfolio optimization, and capital allocation. We recognize that drug development failures, delays, and rising costs are rarely driven by clinical efficacy alone. They result from a complex interplay of operational, strategic, regulatory, commercial, and financial risks. Sorintellis is designed to address these challenges holistically bringing clarity, transparency, and actionable intelligence to high-stakes R&D decisions. Our vision is clear: to revolutionize clinical trials and pharmaceutical portfolio management through AI-driven decision support that accelerates development timelines and increases the likelihood of success—so life-changing therapies reach patients faster. Join us at contact@sorintellis.ai